GlassScriptPhysician profile
Gregory J Heyt
NPI 1861496572
$4,517.88
in general payments reported to CMS, 2019-2025
34 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $220 · 2021: $162 · 2022: $483 · 2023: $456 · 2024: $1,090 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531 · Education: $27.75 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.24 |
| Education | $27.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,206.30 | 2019-2025 | |
| Janssen Biotech, INC. | $483.62 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $443.49 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $368.90 | 2019-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $230.19 | 2019-2025 | Entyvio, Gattex |
| Janssen Scientific Affairs, LLC | $214.87 | 2022-2024 | Tremfya |
| Gilead Sciences, INC. | $174.07 | 2023-2025 | Epclusa |
| Genzyme Corporation | $156.89 | 2022-2025 | |
| Qol Medical, LLC | $138.70 | 2019-2024 | Sucraid |
| Lilly USA, LLC | $136.42 | 2024-2025 | Omvoh, Zepbound |
| Ferring Pharmaceuticals INC. | $116.97 | 2019-2023 | Cimzia, Rebyota |
| Intercept Pharmaceuticals, INC. | $98.78 | 2019-2024 | Ocaliva |
| Celgene Corporation | $98.32 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $87.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $76.00 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.18 | 2023-2024 | Cyltezo |
| Braintree Laboratories, INC. | $40.81 | 2019-2025 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $39.39 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $38.40 | 2023 | |
| Ucb, INC. | $37.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $36.87 | 2023-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $32.77 | 2025 | Iqirvo |
| Ethicon US, LLC | $28.48 | 2019 | |
| Alfasigma USA, INC. | $27.36 | 2020 | |
| Phathom Pharmaceuticals, INC. | $23.76 | 2025 | Voquezna |
| Ardelyx, INC. | $19.61 | 2025 | Ibsrela |
| Novo Nordisk INC | $18.31 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $15.19 | 2023 | |
| Shionogi INC | $14.82 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.73 | 2020 | |
| Shire North American Group INC | $14.22 | 2019 | |
| Organon LLC | $13.93 | 2023 | Renflexis |
| Allergan, INC. | $11.59 | 2019 | |
| Redhill Biopharma INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Heyt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.